NeuroPace is evaluating its RNS therapy, including NAUTILUS data, with the FDA and CMS, showing seizure reduction in trial patients.
4 reports, 2 independent
Updated Aug 11
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NeuroPace is evaluating its RNS therapy, including NAUTILUS data, with the FDA and CMS, showing seizure reduction in trial patients.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA rejected NeuroPace's submission for its therapy.1 source
- Joel Becker commented on CMS reimbursement decisions regarding NeuroPace's therapy.Sub-event
NeuroPace is evaluating RNS therapy with FDA and CMS, showing seizure reduction in trial patients.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- themarketsdaily.comNeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
- GlobeNewswireNeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance -- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guid